Immunopathology and Infectious Diseases

4SC-101, A Novel Small Molecule Dihydroorotate Dehydrogenase Inhibitor, Suppresses Systemic Lupus Erythematosus in MRL-(Fas)lpr Mice

Onkar P. Kulkarni,* Sufyan G. Sayyed,* Claudia Kantner,* Mi Ryu,* Max Schnurr,† Miklós Sárdy,‡ Johann Leban,§ Robert Doblihofer,§ and Hans-Joachim Anders*

From the Medizinische Poliklinik-Innenstadt,* Medizinische Klinik-Innenstadt,† and Department of Dermatology and Allergology,‡ University of Munich, Munich; and 4SC AG,§ Planegg-Martinsried, Germany

Immunosuppressive treatments of systemic lupus (SLE) remain associated with significant toxicities; hence, compounds with better toxicity profiles are needed. Dihydroorotate dehydrogenase (DHODH) inhibition with leflunomide has proven to be effective in autoimmune diseases including SLE, but leflunomide can cause a variety of side effects. We hypothesized that 4SC-101, a novel DHODH inhibitor with a more favorable toxicity profile, would be as effective as high-dose cyclophosphamide (CYC) in controlling experimental SLE of female MRL(Fas)lpr mice. Daily oral gavage of 30, 100, and 300 mg/kg 4SC-101 from 12 to 22 weeks of age was compared with either vehicle or CYC treatment (30 mg/kg/week, i.p.) in terms of efficacy and toxicity. Three hundred milligrams per kilogram 4SC-101 was as effective as CYC in depleting spleen autoreactive T cells, B cells, and plasma cells as well as the respective DNA and RNA serum autoantibodies. This was associated with a comparable amelioration of the renal, dermal, and pulmonary SLE manifestations of MRL(Fas)lpr mice. However, even the highest dose of 4SC-101 had no effect on bone marrow neutrophil counts, which were significantly reduced in CYC-treated mice. Together, the novel DHODH inhibitor 4SC-101 is as effective as high dose CYC in controlling SLE without causing myelosuppression. Hence, DHODH inhibition with 4SC-101 might be suitable to treat active SLE with fewer side effects than CYC. (Am J Pathol 2010, 176:2840–2847; DOI: 10.2353/ajpath.2010.091227)

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease caused by multiple genetic polymorphisms and immunostimulatory environmental factors, which commonly affects young females. Mild disease manifestations such as fatigue, skin rashes, arthralgia, or fever can usually be controlled by low dose steroids and antimalarials. In many patients, however, autoimmune inflammation of solid organs holds the risk of progressive tissue remodeling and irreversible organ damage, which requires treatment with potent immunosuppressive drugs. For example, high dose cyclophosphamide (CYC) or mycophenolate mofetil has proven to be effective to control diffuse proliferative lupus nephritis in up to 60% to 80% of patients, and similar protocols have been applied in SLE patients with other types of severe immunopathologies. However, controlled trials revealed that immunosuppressive treatments are associated with significant morbidity and mortality in SLE. For example, in the Aspreva Lupus Management Study, mycophenolate mofetil caused serious adverse effects in 27.7% of patients and treatment-related death in 4.9% of patients; CYC caused serious adverse effects in 22.8% of patients and treatment-related death in 2.8% of patients. Most of the adverse effects and deaths were related to serious infections caused by the immunosuppressive and unspecific antiproliferative effects of CYC and mycophenolate mofetil, evident by myelosuppression and leukopenia. Novel drugs that can control autoimmune tissue inflammation more specifically, ie, without causing myelosuppression, may allow to further improve SLE treatment and to reduce the toxicity of current treatment protocols.
The enzyme dihydroorotate dehydrogenase (DHODH) catalyzes the fourth step in the de novo biosynthesis of pyrimidine by converting dihydroorotate to orotate. This process is an important step in rapidly proliferating cells; hence, DHODH activity is necessary for the rapid expansion of autoreactive lymphocytes in autoimmune diseases. Because the α- and β-barrel domains of DHODH form a tunnel to the active site of enzymatic activity, compounds interacting with the α- and β-barrel domains can block DHODH activity. For example, leflunomide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-isoxazole-4-carboxamide, inhibits DHODH by binding into this tunnel. Consistent with the role of DHODH in lymphocyte proliferation, leflunomide has proven effective and was approved for the treatment of rheumatoid arthritis and psoriasis arthritis. Leflunomide was shown to control lupus nephritis in experimental SLE, but this study lacked a detailed description of the autoimmune phenotype of experimental SLE, a comparison with CYC treatment efficacy or of toxicity aspects. Side effects of leflunomide treatment include diarrhea, arterial hypertension, liver dysfunction, myelosuppression, and interstitial lung disease. It remains unclear whether these effects relate to DHODH inhibition or to off-target effects of leflunomide.

4SC-101, 2-(3-fluoro-3-methoxyphenyl-4-carbamoyl)cyclopent-1-enecarboxylic acid (formerly SC12267), is a novel small molecule DHODH inhibitor. The chemical structure of 4SC-101 (Figure 1) is considerably different from the active metabolite of leflunomide. 4SC-101 inhibits human DHODH with a half maximal inhibitory concentration (IC_{50}) value of 134 nmol/L, and the proliferation of phytohemagglutinin-stimulated lymphocytes with an IC_{50} value of about 13 μmol/L. 4SC-101 inhibits phytohemagglutinin-induced interleukin-17 secretion from human peripheral blood mononuclear cells (PBMCs) in a dose-related fashion with an estimated IC_{50} of 6 μmol/L and independently of lymphocyte proliferation. Because 4SC-101 is active in rodent models of arthritis and intestinal inflammation (own unpublished data), the compound is currently under clinical development for rheumatoid arthritis and inflammatory bowel disease. Can DHODH inhibition with 4SC-101 also control severe SLE? We hypothesized 4SC-101 to be effective in controlling experimental SLE, and we compared its effects with CYC in terms of efficacy and toxicity.

Materials and Methods

Biochemistry and Pharmacological Profile of 4SC-101

In vitro DHODH inhibition assay mixture contained 50 μmol/L decyclouibiquinone, 100 μmol/L dihydroorotate, and 60 μmol/L 2,6-dichlorindophenol. The amount of enzyme was adjusted such that an average slope of approximately 0.2 AU/min will be achieved in the assay for the positive control (eg, without inhibitor). Measurements were conducted in 50 mmol/L TrisHCl, 150 mmol/L KCl, 0.1% Triton X-100, and pH 8.0 at 30°C in a final volume of 1 ml. The components were mixed, and the reaction was started by adding dihydroorotate. The reaction was followed spectrophotometrically by measuring the decrease in absorption at 600 nm for 2 minutes. The assay was linear in time and enzyme concentration. Inhibitory studies were conducted in a standard assay with additional variable amounts of inhibitor. For the determination of the IC_{50} values (concentration of inhibitor required for 50% inhibition), eight different inhibitor concentrations were applied. Each data point was recorded in triplicates on a single measurement day.

Human PBMCs from healthy human donors were purified by centrifugation over Ficoll-Hypaque (Sigma-Aldrich, Taufkirchen, Germany). Purified PBMCs were then washed twice with phosphate-buffered saline and resuspended in RPMI1640 culture medium supplemented with 10% heat inactivated fetal calf serum, 1.5 mmol/L L-glutamine, 100 U penicillin/ml, and 100 mg streptomycin/ml. For stimulation studies, PBMCs were seeded at 1 × 10^5 cells/well, stimulated with 2 μg/ml phytohemagglutinin, and treated with compounds at the indicated concentrations for 48 hours. The vehicle for 4SC-101 (4SC AG, Planegg-Martinsried, Germany) was dimethyl sulfoxide (Acros Organics, Fischer Scientific GmbH, Niederrau, Germany). After incubation, proliferation was assessed by using the cell proliferation colorimetric BrdU-enzyme-linked immunosorbent assay kit from Roche (Mannheim, Germany) according to the manufacturer’s instructions.

Animals and Experimental Protocol

Eight-week-old female MRL^lpr/lpr mice were obtained from Harlan Winkelmann (Borchen, Germany) and kept under normal housing conditions in a 12-hour light and dark cycle. Water and standard chow (SSniff, Soest, Germany) were available ad libitum. At the age of 12 weeks, groups of 11 mice each started to receive either 30, 100, or 300 mg/kg/day 4SC-101 in 100 μl of suspension or placebo suspension only by daily oral gavage. Another group of MRL^lpr/lpr mice received 30 mg/kg CYC once a week by intraperitoneal injection because this dose potently suppresses the autoimmune syndrome in MRL^lpr/lpr mice. Twelve-week-old mice were selected because in our hands the presence of serum autoantibodies and aluminuria indicate significant systemic autoimmunity and early lupus nephritis at this age. 4SC-101 plasma levels were determined at various time intervals after the first
dose. All experiments were performed according to German animal protection laws and had been approved by the local government authorities.

**Evaluation of Systemic Lupus**

Urinary albumin/creatinine concentration ratios and serum immunoglobulin concentrations were determined by enzyme-linked immunosorbent assay as previously described. Two-micrometer paraffin sections for hematoxylin and eosin and periodic acid-Schiff stains were prepared from skin, lung, and kidney tissues samples following routine protocols. Skin lesions were scored semiquantitatively as described. In brief, hematoxylin and eosin skin sections were analyzed for the degree of acanthosis, mildly (1) to very markedly thickened epidermis (3); hyperkeratosis, mildly (1) or markedly increased thickness of the corneal layer (2); interface liquefaction, focal (1) or extensive damage to the basal cell layer (2); inflammation, sparse (1) or intense dermal lymphocytic cell infiltrates (2); fibrosis or mucin deposits, increased dermal cellularity with slight (1) or markedly thickened extracellular matrix or mucin deposits (2); vessels, focal (1) or diffuse (2) distribution of hemorrhagic vasodilation; and loss of epidermis, absence (0) or presence (1) of ulcer or erosion. The severity of the renal lesions was graded by using the indices for activity and chronicity as described for human lupus nephritis. The severity of the peribronchial inflammation was graded semiquantitatively from 0 to 3. Immunostaining was performed as previously described. The following primary antibodies were used: rat anti-mouse Mac2 (macrophages, Cederlane, ON, Canada, 1:50); anti-mouse CD3 (1:100, clone 500A2, BD Pharmingen, Heidelberg, Germany); and anti-mouse IgG, (1:100, M32015, Caltag Laboratories, Burlingame, CA). Glomerular Ig deposits were scored from 0 to 3 on 15 glomerular sections where 0 = no glomerular IgG deposits, 1 = trace IgG deposits, 2 = moderate IgG deposits, and 3 = severe IgG deposits. Glomerular cells were counted in 15 cortical glomeruli per section. Interstitial cells were counted in 15 high power fields per section. All quantitative and semiquantitative analyses were performed by three blinded observers (Claudia Kanter, Miklos Sardy, Hans-J. Anders).

**Glomerular Filtration Rate**

Glomerular filtration rate (GFR) was determined by clearance kinetics of plasma fluorescein isothiocyanate (FITC)-inulin (Sigma-Aldrich) 5, 10, 15, 20, 35, 60, and 90 minutes after a single intravenous bolus injection. Fluorescence was determined with 485 nm excitation and read at 535 nm emission. GFR was calculated based on a two-compartment model of nonlinear regression by using a curve-fitting software (GraphPad Prism, GraphPad Software, Inc., San Diego, CA).

**Flow Cytometry**

Flow cytometry was performed by using a FACScalibur machine using the following primary antibodies: anti-mouse CD4-APC, CD8-PerCp, CD3-FITC, CD25-PerCp, CD45R-AF647, and CD19-PerCp. Glomerular Ig deposits were scored from 0 to 3.

---

### Table 1. Pharmacodynamics of 4SC-101

<table>
<thead>
<tr>
<th>Inhibition of</th>
<th>4SC-101 (IC50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human DHODH</td>
<td>0.048 ± 0.006 μg/ml (0.134 ± 0.016 μmol/L)</td>
</tr>
<tr>
<td>Rat DHODH</td>
<td>0.46 ± 0.17 μg/ml (1.29 ± 0.47 μmol/L)</td>
</tr>
<tr>
<td>Mouse DHODH</td>
<td>3.8 ± 0.5 μg/ml (10.6 ± 0.7 μmol/L)</td>
</tr>
<tr>
<td>Human PBMC proliferation</td>
<td>4.6 ± 2.1 μg/ml (12.9 ± 5.9 μmol/L)</td>
</tr>
</tbody>
</table>

### Table 2. Pharmacokinetics of 4SC-101

<table>
<thead>
<tr>
<th>Dose, mg/kg</th>
<th>Cmax, μg/ml</th>
<th>tmax, h</th>
<th>AUC0-24h, μg/ml</th>
<th>t1/2, h</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>28.4</td>
<td>1.0</td>
<td>229.0</td>
<td>2.3</td>
</tr>
<tr>
<td>100</td>
<td>46.0</td>
<td>1.5</td>
<td>499.7</td>
<td>2.3</td>
</tr>
<tr>
<td>300</td>
<td>52.1</td>
<td>1.5</td>
<td>583.3</td>
<td>3.0</td>
</tr>
</tbody>
</table>

C<sub>max</sub> maximal concentration after single injection; t<sub>max</sub>, time point of maximal concentration after single injection; AUC, area under the curve; t<sub>1/2</sub>, maximal concentration half time.

---

**Results**

### Pharmacodynamics of 4SC-101

DHODH inhibition was confirmed in an in vitro enzyme assay, which allows one to monitor the catalytic activity of the enzyme by indirect measurement of the reduced co-substrate ubiquinone. 4SC-101 caused a concentration-dependent inhibition of DHODH. The inhibition data for 4SC-101 in different DHODH species are given in Table 1. Human peripheral blood mononuclear cells isolated from healthy donors were stimulated with 2 μg/ml phytohemagglutinin. 4SC-101 caused a concentration-dependent inhibition of phytohemagglutinin-stimulated PBMC proliferation. The IC<sub>50</sub> values were determined by nonlinear regression of the inhibition curves by using a Hill equation curve fitting. The resulting data are given in Table 1. The inhibition of PBMC proliferation by 4SC-101 could be abrogated by addition of 50 to 500 μmol/L of uridine to the assay mixture, supporting the inhibition of pyrimidine de novo synthesis as the mode of action (data not shown).
Pharmacokinetics of Single Dose 4SC-101 in MRL<sup>lpr/lpr</sup> Mice

Pharmacokinetic studies were performed in 12-week-old female MRL<sup>lpr/lpr</sup> mice (n = 3 for each dose and time point). Pharmacokinetic parameters were calculated from geometric mean plasma levels per time point. Area under the curve was calculated by using the trapezoidal rule and extrapolated to infinity by adding Cz/Ax. Key pharmacokinetic parameters are listed in Table 2. Plasma concentrations increased with increasing doses of 4SC-101, though, less than dose-proportionally (Figure 2). Maximum plasma levels were reached after 60 to 90 minutes, and the terminal half-life was 2.3 to 3 hours. Due to the lack of data points in the terminal phase, the values calculated for t<sub>1/2</sub> were probably underestimated.

Long-term 4SC-101 Treatment and B and T Cell Immunity in MRL<sup>lpr/lpr</sup> Mice

Next we assessed the effects of a long-term exposure with 4SC-101 on SLE in female MRL<sup>lcr/lpr</sup> mice. Mice were treated from 12 to 22 weeks of age with either 30, 100, or 300 mg/kg/day 4SC-101 by daily oral gavage. Additional groups of mice were treated either with placebo daily oral gavage or with CYC (30 mg/kg per week, i.p.) to serve as negative and positive controls, respectively. CYC and 300 mg/kg 4SC-101 were equipotent in reducing the weight of mesenterical lymph nodes at 22 weeks of age (Figure 3A). 4SC-101 at a dose of 100 mg/kg was less effective, and lymph node weight in the 30 mg/kg dose group was not significantly different from vehicle-treated MRL<sup>lcr/lpr</sup> mice (Figure 3A). Flow cytometry of spleen lymphocyte subsets revealed that 300 mg/kg 4SC-101 and CYC both significantly reduced the numbers of splenic CD3<sup>+</sup> lymphocytes, mainly by reducing CD4<sup>+</sup> T helper cells and CD4<sup>+</sup>CD8<sup>+</sup> double negative "autoactive" T cells (Figure 3B). By contrast, 300 mg/kg 4SC-101 did not significantly alter the CD8<sup>+</sup> "cytotoxic" and CD4<sup>+</sup>/CD25<sup>+</sup> "regulatory" T cell populations (Figure 3B). The lower doses of 4SC-101 had no significant effect on T cell populations in spleens of 22-week-old female MRL<sup>lcr/lpr</sup> mice. However, 100 and 300 mg/kg 4SC-101 both significantly reduced the B220<sup>+</sup>IgM<sup>+</sup>IgD<sup>+</sup> "mature" B cells, the B220<sup>+</sup>CD21<sup>high</sup>CD23<sup>low</sup> "marginal zone" B cells, the B220<sup>+</sup>CD21<sup>low</sup>CD23<sup>high</sup> "follicular" B cells, and the cyttoplasmic κ<sup>+</sup>CD138<sup>+</sup> plasma cells (Figure 3C). Interestingly, CYC did not significantly affect these B cell populations in MRL<sup>lcr/lpr</sup> mice, indicating that 4SC-101 has a
predominant effect on B cells, which is different to the immunosuppressive effects of CYC. In addition, 300 mg/kg 4SC-101 and CYC significantly reduced serum total IgG and IgG isotype levels in 22-week-old female MRL(lpr/lpr) mice (Figure 3D). This effect did also apply to the production of lupus autoantibodies because anti-dsDNA IgG serum levels were only significantly reduced in the 300 mg/kg 4SC-101 and CYC groups (Figure 3E). Thus, reducing T cells is more important than reducing B cells to suppress hypergammaglobulinemia and autoantibody production in female MRL(lpr/lpr) mice, which was achieved by 300 mg/kg 4SC-101 and CYC.

**4SC-101 Improves Lupus Nephritis in MRL(lpr/lpr) Mice**

Female MRL(lpr/lpr) mice develop and subsequently die from proliferative immune complex glomerulonephritis with large similarities to diffuse proliferative lupus nephritis in humans. We treated female MRL(lpr/lpr) mice with 4SC-101, CYC, or vehicle from 12 to 22 weeks of age because at 12 weeks of age MRL(lpr/lpr) mice show first signs of proliferative immune complex glomerulonephritis and proteinuria. After 10 weeks of treatment, vehicle-treated MRL(lpr/lpr) mice showed diffuse proliferative immune complex glomerulonephritis characterized by glomerular IgG deposits, mesangio proliferative glomerulonephritis, considerable tubular atrophy, and interstitial fibrosis (Figure 4A). 4SC-101 reduced the glomerular IgG deposits and improved the lupus-like immune complex glomerulonephritis in female MRL(lpr/lpr) mice in a dose dependent manner (Figure 4A) as evidenced by semiquantitative morphometrical evaluation, eg, by assessing the activity and chronicity scores of lupus nephritis (Figure 4B). The activity score, a composite score of mostly glomerular abnormalities, and glomerular IgG deposits were significantly reduced by 100 as well as by 300 mg/kg 4SC-101 (Figure 4B). The chronicity score, a composite score of glomerular and interstitial scarring, was significant for the 300 mg/kg 4SC-101 group only. CYC was potent in reducing both parameters but not significantly different from 300 mg/kg 4SC-101. In 22-week-old vehicle-treated MRL(lpr/lpr) mice, lupus nephritis was associated with glomerular macrophage infiltration and a mixed periglomerular and interstitial inflammatory cell infiltrate consisting of glomerular and interstitial Mac2-positive macrophages and interstitial CD3-positive T cells (Figure 4A). CYC and 100 and 300 mg/kg 4SC-101 reduced renal macrophage and T cell infiltrates (Figure 4C).

![Figure 4](image-url)
Next we determined the GFR as a functional marker of renal excretory function and urinary albumin/creatinine ratio as a marker of proteinuria, ie, glomerular filtration barrier dysfunction. 4SC-101 treatment was associated with an increase of GFR and a decrease of albuminuria in a dose-dependent manner (Figure 5, A and B). Doses of 100 or 300 mg/kg 4SC-101 were both as effective as CYC in improving both of these renal function parameters. We conclude that the dose-dependent impact of 4SC-101 on systemic autoimmunity translates into anti-inflammatory effects on lupus nephritis and improvement of renal dysfunction in MRL lpr/lpr mice.

4SC-101 Reduces Cutaneous and Pulmonary SLE Manifestations of MRL lpr/lpr Mice

Skin and lungs are also commonly affected by autoimmune tissue injury in MRL lpr/lpr mice. In vehicle-treated mice, 6 of 11 mice suffered either from facial rash and/or discoid lesions in the neck area, few of them with neck ulcers. Histopathological evaluation of neck skin revealed various degrees of acanthosis, hyperkeratosis, widening of the interface, T cell infiltrates, dermal mucin and collagen deposits, and vasodilatation (Figure 6A). The quantitative assessment of a composite score of all of these abnormalities revealed a dose-dependent improvement of skin disease in 4SC-101-treated female MRL lpr/lpr mice (Figure 6B). All of the aforementioned parameters were significantly improved by 300 mg/kg 4SC-101 except for dermal fibrosis (Figure 6C). None of the CYC-treated mice revealed any signs of skin disease. Autoimmune lung disease in MRL lpr/lpr mice was characterized by moderate to severe peribronchiolar and perivascular inflammatory cell infiltrates (Figure 7A). All dose regimens of 4SC-101 were effective in reducing lung pathology as evidenced by a semiquantitative lung injury score (Figure 7B). Obviously, higher doses of 4SC-101 are as potent as CYC to control kidney, skin, and lung pathology in autoimmune MRL lpr/lpr mice.

4SC-101 and Bone Marrow Cells in MRL lpr/lpr Mice

The therapeutic use of CYC is generally limited by myelosuppression, potentially causing fatal infectious complications, a side effect resulting from the unspecific antiproliferative mode of CYC action. We therefore performed flow cytometry on bone marrow cell suspensions to compare the effects of 4SC-101 and CYC on myelosuppression. CYC treatment significantly reduced the number of neutrophils in bone marrows to less than 30% and the mixed leukocyte population (monocytes, T cells and B cells) by 50% compared with vehicle-treated MRL lpr/lpr mice (Figure 8). By contrast, none of the 4SC-101 dose groups showed reduced bone marrow neutrophils (or macrophages) counts. We therefore conclude that a broad dose range of 4SC-101 does not cause myelosuppression in MRL lpr/lpr mice, which is one of the major risk factors for infectious complications during immunosuppressive therapy of SLE.
Discusion

Immunosuppressants like CYC remain first-line treatment for severe SLE. However, many patients suffer from severe side effects like myelosuppression making patients susceptible to life threatening infections. Our data show that 4SC-101 is as effective as CYC in controlling SLE in MRL lpr/lpr mice but avoid these side effects.

The novel DHODH inhibitor 4SC-101 acts as a highly selective inhibitor of the de novo biosynthesis of pyrimidines, which inhibits the expansion of rapidly proliferating cells. DHODH inhibition was thought to be appropriate in SLE because the expansion of autoreactive lymphocytes demands large quantities of pyrimidine to support DNA synthesis, which renders autoreactive lymphocytes especially sensitive to the blockade of pyrimidine de novo synthesis. We found that 300 mg/kg of 4SC-101 can significantly reduce the numbers of CD4/CD8 double negative “autoreactive” T cells and plasma cells in spleen without affecting CD4/CD25+ “regulatory” T cells. This suppressive effect was sufficient to significantly reduce hypergammaglobulinemia and dsDNA autoantibodies as major hallmarks of polyclonal autoimmunity in SLE. Consistent with the concept of systemic autoimmunity driving tissue pathology, the reduction of autoreactive T and B cells was associated with almost complete prevention of cutaneous lupus lesions in all layers of the skin, improved renal pathology and function, and significant improvement of lung pathology. In terms of toxicity, CYC treatment caused significant myelosuppression as in our previous studies. Bone marrow 7/4+ monocytes and neutrophils were reduced by CYC treatment but not by 4SC-101, a finding not revealed by a study describing DHODH inhibition with leflunomide in murine SLE, basically because bone marrow was not analyzed.

What is the clinical perspective of DHODH inhibition in human SLE? A double-blind, randomized, placebo-controlled study proved leflunomide to be effective in controlling diverse SLE manifestations in a small number of patients and during short-term follow-up. One patient withdrew from the study due to liver toxicity, and two patients discontinued treatment because of hypertension; both known side effects of leflunomide. The same group determined safety and efficacy of leflunomide in 17 patients with lupus nephritis with previous treatment-related toxicities, CYC contraindications or lack of response to CYC, azathioprine, or cyclosporin for at least 6 months. Leflunomide induced a partial remission in 13 of 17 patients and a complete remission in 5 of 17 patients, which serves as another proof-of-concept that DHODH inhibition can control severe SLE. However, leflunomide treatment was associated with hypertension in 6 of 17 patients and infections in 4 of 17 patients. Another trial compared efficacy and safety of leflunomide and CYC in 110 patients with biopsy-proven diffuse-proliferative lupus nephritis. Leflunomide was found to be equally effective as compared with CYC but caused the well known side effects. It is unknown whether these side effects are leflunomide-specific or a result of DHODH inhibition. The observation that leflunomide can induce cutaneous lupus may argue for drug-specific side effects rather than for DHODH inhibition. 4SC-101 has been clinically tested in over 140 patients and healthy volunteers so far. In a randomized, double-blind, placebo-controlled phase II study, the safety, tolerability, and pharmacokinetics of ascending single oral doses of 4SC-101 (study number SC12267-1-2003) were evaluated in 42 healthy volunteers. In a corresponding phase I trial testing ascending multiple oral doses of 4SC-101 (study number SC12267-2-2004), additional 24 healthy volunteers have been treated with 4SC-101. In a randomized, double-blind, placebo-controlled phase IIa proof of concept study in rheumatoid arthritis (study number SC12267-
3-2005), a total of 121 patients were randomized to three treatment groups (about 40 patients per group) to receive 20 mg tablets of 4SC-101, 35 mg tablets of 4SC-101, or matching placebo tablets once daily for a period of 12 weeks. In all completed trials, no liver toxicity, diarrhea, or arterial hypertension have been observed as treatment-related adverse events. 4SC-101 is currently being tested in two further ongoing phase II clinical trials: the “ENTRANCE” trial evaluating 4SC-101 in patients with inflammatory bowel diseases (http://www.clinicaltrials.gov, identifier: NCT00820365) and the “COMPONENT” trial assessing the efficacy of 4SC-101 in rheumatoid arthritis patients in combination with methotrexate (http://www.clinicaltrials.gov, identifier: NCT01010581).

In conclusion, so far 4SC-101 has been shown to be safe in human clinical trials without causing arterial hypertension, abnormal liver function tests, myelosuppression, or skin disease. Hence, 4SC-101 might be as effective as leflunomide or CYC in controlling severe SLE with fewer side effects.

Acknowledgments

The expert technical assistance of Dan Draganoic and Ewa Radomska is gratefully acknowledged.

References


DHODH Inhibition in SLE

AJF June 2010, Vol. 176, No. 6